Aristotle Atlantic Partners LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.9% during the fourth quarter, HoldingsChannel reports. The firm owned 235,611 shares of the medical device company’s stock after purchasing an additional 42,334 shares during the period. Aristotle Atlantic Partners LLC’s holdings in DexCom were worth $15,638,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after purchasing an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after purchasing an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 6.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank bought a new position in shares of DexCom during the 4th quarter valued at $483,356,000. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of DexCom by 7.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.
Insider Buying and Selling at DexCom
In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock worth $3,343,977 over the last three months. 0.28% of the stock is owned by corporate insiders.
DexCom Stock Performance
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 EPS. Equities research analysts predict that DexCom, Inc. will post 2.58 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. UBS Group set a $95.00 target price on DexCom in a research note on Wednesday, June 10th. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. Finally, TD Cowen reissued a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $84.83.
Read Our Latest Stock Report on DXCM
DexCom Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Articles
- Five stocks we like better than DexCom
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
